Zigakibart is under clinical development by Novartis and currently in Phase III for IgA Nephropathy (Berger's Disease).

Novaferon is under clinical development by Genova Biotech and currently in Phase III for Coronavirus Disease 2019 (COVID-19).

Danazol is under clinical development by Viramal and currently in Phase II for Endometriosis. According to GlobalData, Phase II drugs for Endometriosis have a 30% phase transition success rate (PTSR) ...

EF-001 is under clinical development by Everfront Biotech and currently in Phase II for High-Grade Glioma. According to GlobalData, Phase II drugs for High-Grade Glioma does not have sufficient ...

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, ...

ENERGIF-703 is under clinical development by Energenesis Biomedical and currently in Phase III for Diabetic Foot Ulcers.

VIR-5818 is under clinical development by Vir Biotechnology and currently in Phase II for Metastatic Breast Cancer.

CY-101 is under clinical development by Cytovation and currently in Phase II for Liver Cancer. According to GlobalData, Phase II drugs for Liver Cancer have a 31% phase transition success rate (PTSR) ...

ZW-171 is under clinical development by Zymeworks and currently in Phase I for Ovarian Cancer. According to GlobalData, Phase I drugs for Ovarian Cancer have a 73% phase transition success rate (PTSR) ...

AGEN-2373 is under clinical development by Agenus and currently in Phase I for Adrenal Gland Cancer. According to GlobalData, Phase I drugs for Adrenal Gland Cancer have an 84% phase transition ...

TQB-2223 is under clinical development by Chia Tai Tianqing Pharmaceutical Group and currently in Phase I for Solid Tumor.

Onvapegleukin alfa is under clinical development by Ascendis Pharma and currently in Phase II for Human Papillomavirus (HPV) Associated Cancer.